A Phase III Clinical Trial to Study the Immunogenicity, Tolerability, and Manufacturing Consistency of V503 (A Multivalent Human Papillomavirus [HPV] L1 Virus-Like Particle [VLP] Vaccine) in Preadolescents and Adolescents (9 to 15 Year Olds) With a Comparison to Young Women (16 to 26 Year Olds)

MERCK SHARP & DOHME PERU S.R.L.,0 sites0 target enrollmentSeptember 9, 2009

Overview

Phase: 未知
Intervention: Not specified
Conditions: Not specified
Sponsor: MERCK SHARP & DOHME PERU S.R.L.,
Status: Completed
Last Updated: 2 years ago

Overview Investigators Eligibility Criteria Outcomes Similar Trials

Overview

Brief Summary

No summary available.

Registry

who.int

Start Date

September 9, 2009

End Date

TBD

Last Updated

2 years ago

Study Type

Interventional

Investigators

Sponsor

MERCK SHARP & DOHME PERU S.R.L.,

Eligibility Criteria

Inclusion Criteria

•Subject is male or female, between the ages of 9 years and 0 days and 15 years and 364 days on the day of enrolment, or the subject is female between the ages of 16 years and 0 days and 26 years and 364 days on the day of enrollment.
•Subjects age 9\-15 must not yet have had first sexual intercourse and does not plan on becoming sexually active during the Day 1 through Month 7 period.
•Subjects age 16\-26 have a lifetime history of 0 to 4 male and/or female sexual partners at the time of enrollment.
•Subject has never had Pap testing or has only had normal Pap test results.
•Subject (or, for minor subjects, parent/legal guardian and subject) fully understands study procedures, alternative treatments available, the risks involved with the study, and voluntarily agrees to participate by giving written informed consent.

Exclusion Criteria

•Subject is pregnant (as determined by a serum pregnancy test or urine pregnancy test that is sensitive to 25 mIU/mL ß\-hCG).
•Subject has received a marketed HPV vaccine, or has participated in an HPV vaccine clinical trial and has received either active agent or placebo.
•Subject is concurrently enrolled in clinical studies of investigational agents or studies involving collection of cervical specimens.
•Subject has a known allergy to any vaccine component, including aluminum, yeast, or BENZONASE™ (nuclease, Nycomed \[used to remove residual nucleic acids from this and other vaccines]).
•Subject is currently immunocompromised or has been diagnosed as having a congenital or acquired immunodeficiency, HIV infection, lymphoma, leukemia, systemic lupus erythematosus (SLE), rheumatoid arthritis, juvenile rheumatoid arthritis (JRA), inflammatory bowel disease, or other autoimmune condition.
•Subject has a history of an abnormal cervical biopsy result (showing cervical intraepithelial neoplasia \[CIN] or worse).
•Subject has a history of or clinical evidence at the Day 1 pelvic examination of HPV\-related external genital lesions (e.g., condyloma acuminata or vulvar intraepithelial neoplasia \[VIN]) or external genital cancer, HPV\-related vaginal lesions (e.g., condyloma acuminata or vaginal intraepithelial neoplasia \[VaIN]) or vaginal cancer.

Outcomes

Primary Outcomes

Not specified

Similar Trials

Active, not recruiting

Phase 1

Immunogenicity, Tolerability, and Manufacturing Consistency study of a Multivalent HPV, VLP vaccinePrevention of cervical, vulvar, and vaginal cancers and related precancers, externalgenital lesions, Pap test abnormalities, and persistent infection caused by humanpapillomavirus (HPV) Types 6, 11, 16, 18, 31, 33, 45, 52, and 58.MedDRA version: 20.1Level: LLTClassification code 10063001Term: Human papilloma virus infectionSystem Organ Class: 100000004862Therapeutic area: Body processes [G] - Immune system processes [G12]

EUCTR2009-011617-25-BEMerck Sharp & Dohme Corp., a subsidiary of Merck & Co.,2,000

Completed

Phase 3

A Study of V503 (Multivalent HPV Vaccine) in Preadolescents and Adolescents. This study will evaluate the immunogenicity and tolerability of V503 in preadolescent and adolescent subjects between 9 and 15 years old and demonstrate the consistency of the manufactured vaccine through assessment of 3 different final manufacturing process lots of V503.Health Condition 1: C539- Malignant neoplasm of cervix uteri, unspecified

CTRI/2009/091/000767Merck Sharp and Dohme2,800

Active, not recruiting

Phase 3

This study will evaluate the immunogenicity and tolerability of V503 ipreadolescent and adolescent subjects between 9 and 15 years old andemonstrate the consistency of the manufactured vaccine throughassessment of 3 different final manufacturing process lots of V503.

CTRI/2013/09/004012Merck Sharp and Dohme2,800

Active, not recruiting

Phase 1

A Phase III Clinical Trial to Study the Immunogenicity, Tolerability, and Manufacturing Consistency of V503 (A Multivalent Human Papillomavirus [HPV] L1 Virus-Like Particle [VLP] Vaccine) in Preadolescents and Adolescents (9 to 15 year olds) with a Comparison to Young Women (16 to 26 year olds)Cervical CancersVulvar CancerVaginal CancerGenital LesionsPAP Test AbnormalitiesHPV InfectionsMedDRA version: 20.1Level: LLTClassification code 10063001Term: Human papilloma virus infectionSystem Organ Class: 100000004862Therapeutic area: Diseases [C] - Virus Diseases [C02]

EUCTR2009-011617-25-Outside-EU/EEAMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.

Active, not recruiting

Phase 1

Immunogenicity, Tolerability, and Manufacturing Consistency study of aMultivalent HPV, VLP vaccine.Prevention of cervical, vulvar, and vaginal cancers and related precancers, external genital lesions, Pap test abnormalities, and persistent infection caused by human papillomavirus (HPV) Types 6, 11, 16, 18, 31, 33, 45, 52, and 58.MedDRA version: 20.0Level: LLTClassification code 10063001Term: Human papilloma virus infectionSystem Organ Class: 100000004862Therapeutic area: Body processes [G] - Immune system processes [G12]

EUCTR2009-011617-25-PLMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.3,123